Skip to main content
Premium Trial:

Request an Annual Quote

Expression Pathology, Flagship Partner to Offer Translational Biomarker Services

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expression Pathology and Flagship Biosciences today announced a service partnership to enable tissue translational biomarker development, validation, and application to support new drug development.

The new offering combines Expression's expertise in multiplex tissue proteomic assays using frozen formalin, paraffin-fixed tissues with Flagship's pathology expertise.

Based in Flagstaff, Ariz., Flagship provides digital pathology services. Expression is based in Gaithersburg, Md., and develops assays to measure functional tissue proteins.

Customers of both firms will now be able to "leverage expertise with tissue biomarkers to quickly develop quantitative evidence-based assays using the combined know how of mass spec tissue analysis and digital pathology," Flagship said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.